Related Experiment Video
Updated: Jul 18, 2026
09:03
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Adrenomedullin: a tumor progression factor via angiogenic control
Misa Nakamura1, Bo Han, Osamu Nunobiki
1Department of Pathology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. nakamuram@kawasakigakuen.ac.jp
Current Cancer Drug Targets
|November 15, 2006
Summary
Adrenomedullin (ADM) is a peptide involved in various diseases, including cancer. This review focuses on ADM's role in cancer, highlighting its diagnostic, prognostic, and therapeutic potential.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Adrenomedullin (ADM) is a 52-amino acid peptide homologous to CGRP.
- ADM is produced in various mammalian tissues and implicated in cardiovascular, renal, inflammatory, and cancerous diseases.
- ADM is expressed in numerous tumors, promoting cancer cell growth and survival.
Purpose of the Study:
- To review the role of Adrenomedullin (ADM) in cancer.
- To explore ADM's utility in cancer diagnosis and prognosis.
- To discuss ADM as a potential therapeutic target in oncology.
Main Methods:
- Literature review of studies on Adrenomedullin (ADM).
- Analysis of ADM's function in cancer cell proliferation, survival, and angiogenesis.
- Evaluation of ADM's diagnostic and prognostic value in various cancers.
Main Results:
- ADM acts as a mitogenic and survival factor for cancer cells.
- ADM promotes angiogenesis, particularly in hypoxic tumor environments.
- ADM expression correlates with disease progression and can serve as a biomarker.
Conclusions:
- Adrenomedullin (ADM) plays a significant role in cancer development and progression.
- ADM holds promise as a diagnostic and prognostic biomarker for cancer.
- Targeting ADM presents a potential therapeutic strategy for cancer treatment.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...